Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085374 | 1.00 | HTR2C (0.49) | HTR2CHTR2AHTR2BADRB2IDO1 | |
| SCHEMBL4083583 | 0.86 | MGAM (0.46) | HTR2CHTR2AHTR2BLMNA | |
| SCHEMBL13620081 | 0.85 | IDO1 (0.50) | IDO1LMNA | |
| SCHEMBL4100331 | 0.84 | HTR2A (0.51) | HTR2CHTR2AHTR2BIDO1 | |
| SCHEMBL3978475 | 0.84 | SLC6A4 (0.50) | IDO1LMNA | |
| SCHEMBL4100338 | 0.84 | HTR2A (0.51) | HTR2CHTR2AHTR2BIDO1 | |
| SCHEMBL4098671 | 0.84 | SLC6A4 (0.50) | HTR2AIDO1 | |
| SCHEMBL4098677 | 0.84 | SLC6A4 (0.50) | HTR2AIDO1 | |
| SCHEMBL4088917 | 0.82 | HTR2A (0.43) | HTR2CHTR2AHTR2BIDO1LMNA | |
| SCHEMBL4097291 | 0.82 | HTR2A (0.43) | HTR2CHTR2AHTR2BIDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
| WO-2008025361-A1 | 3-(1H-INDOL-3-YL) INDAN-1-YLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | OPRL1, HTR2C, SLC6A3 | HTR2C 2/4885HTR2A 15/4885HTR2B 36/4885 |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | GPR119, INSR, IRS1 | HTR2C 76/4885HTR2A 103/4885HTR2B 194/4885 |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | HTR2C 348/4885HTR2A 62/4885HTR2B 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.